Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N A Tsareva

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Terapevticheskii Arkhiv|March 20, 2014
[Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension]N A Tsareva
Terapevticheskii Arkhiv|June 30, 2020
[Risk stratification methods and their significance in pulmonary arterial hypertension]S N Avdeev, N A Tsareva
Kardiologiia|January 10, 2019
N A Tsareva, S N Avdeev
Terapevticheskii Arkhiv|February 1, 2019
Combination therapy is a new standard for treatment of pulmonary arterial hypertensionS N Avdeev, N A TsarEva, I R Gaisin
Terapevticheskii Arkhiv|October 18, 2017
[A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?]N A Tsareva, S N Avdeev, G V Neklyudova
Klinicheskaia Laboratornaia Diagnostika|February 1, 2019
[Natriuretic peptides as markers of development and prognosis of pulmonary hypertension severity in patients with chronic obstructive disease.]S N Avdeev, V V Gaynitdinova, N A Tsareva, et al.
Terapevticheskii Arkhiv|May 31, 2013
[First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study]S N Avdeev, N A tsareva, G V Nekliudova, et al.
Kardiologiia|November 12, 2021
[Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)]A A Proshkina, N A Tsareva, G V Nekludova, et al.
Journal of Molecular Biology|January 31, 1997
Rapid evolution of translational control mechanisms in RNA genomesJ Klovins, N A Tsareva, M H de Smit, et al.
Problemy Sotsial'Noi Gigieny, Zdravookhraneniia I Istorii Meditsiny|November 14, 2025
[THE SOCIOLOGICAL STUDY ON INVESTIGATION OF PREFERENCES IN RECEIVING INFORMATION BY PATIENTS WITH BRONCHI OBSTRUCTIVE DISEASES OF LUNGS]S A Linnik, S A Shvachko, E E Tumenko, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Terapevticheskii Arkhiv|March 20, 2014
[Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension]N A Tsareva
Terapevticheskii Arkhiv|June 30, 2020
[Risk stratification methods and their significance in pulmonary arterial hypertension]S N Avdeev, N A Tsareva
Kardiologiia|January 10, 2019
N A Tsareva, S N Avdeev
Terapevticheskii Arkhiv|February 1, 2019
Combination therapy is a new standard for treatment of pulmonary arterial hypertensionS N Avdeev, N A TsarEva, I R Gaisin
Terapevticheskii Arkhiv|October 18, 2017
[A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?]N A Tsareva, S N Avdeev, G V Neklyudova
Klinicheskaia Laboratornaia Diagnostika|February 1, 2019
[Natriuretic peptides as markers of development and prognosis of pulmonary hypertension severity in patients with chronic obstructive disease.]S N Avdeev, V V Gaynitdinova, N A Tsareva, et al.
Terapevticheskii Arkhiv|May 31, 2013
[First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study]S N Avdeev, N A tsareva, G V Nekliudova, et al.
Kardiologiia|November 12, 2021
[Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)]A A Proshkina, N A Tsareva, G V Nekludova, et al.
Journal of Molecular Biology|January 31, 1997
Rapid evolution of translational control mechanisms in RNA genomesJ Klovins, N A Tsareva, M H de Smit, et al.
Problemy Sotsial'Noi Gigieny, Zdravookhraneniia I Istorii Meditsiny|November 14, 2025
[THE SOCIOLOGICAL STUDY ON INVESTIGATION OF PREFERENCES IN RECEIVING INFORMATION BY PATIENTS WITH BRONCHI OBSTRUCTIVE DISEASES OF LUNGS]S A Linnik, S A Shvachko, E E Tumenko, et al.
Pageof 2